OBI Pharma (4174) - Total Assets
Based on the latest financial reports, OBI Pharma (4174) holds total assets worth NT$3.83 Billion TWD (≈ $120.64 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of OBI Pharma to assess the company's total reinvestment commitment from operating cash flow.
OBI Pharma - Total Assets Trend (2011–2024)
This chart illustrates how OBI Pharma's total assets have evolved over time, based on quarterly financial data. Explore OBI Pharma strategic investment ratio to see how much of total assets are deployed in long-term investments.
OBI Pharma - Asset Composition Analysis
Current Asset Composition (December 2024)
OBI Pharma's total assets of NT$3.83 Billion consist of 60.8% current assets and 39.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 30.6% |
| Accounts Receivable | NT$4.20 Million | 0.1% |
| Inventory | NT$27.73 Million | 0.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how OBI Pharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of OBI Pharma.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OBI Pharma's current assets represent 60.8% of total assets in 2024, a decrease from 88.5% in 2011.
- Cash Position: Cash and equivalents constituted 30.6% of total assets in 2024, up from 10.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 9.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 0.5% of total assets.
OBI Pharma Competitors by Total Assets
Key competitors of OBI Pharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
OBI Pharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.11 | 11.70 | 15.67 |
| Quick Ratio | 5.04 | 11.53 | 15.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.53 Billion | NT$1.55 Billion | NT$3.65 Billion |
OBI Pharma - Advanced Valuation Insights
This section examines the relationship between OBI Pharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.65 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 0.9% |
| Total Assets | NT$5.65 Billion |
| Market Capitalization | $116.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values OBI Pharma's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: OBI Pharma's assets grew by 0.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for OBI Pharma (2011–2024)
The table below shows the annual total assets of OBI Pharma from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$5.65 Billion ≈ $178.12 Million |
+0.89% |
| 2023-12-31 | NT$5.60 Billion ≈ $176.55 Million |
-15.52% |
| 2022-12-31 | NT$6.63 Billion ≈ $209.00 Million |
+47.85% |
| 2021-12-31 | NT$4.49 Billion ≈ $141.36 Million |
-15.98% |
| 2020-12-31 | NT$5.34 Billion ≈ $168.23 Million |
-5.71% |
| 2019-12-31 | NT$5.66 Billion ≈ $178.42 Million |
+20.25% |
| 2018-12-31 | NT$4.71 Billion ≈ $148.37 Million |
-9.26% |
| 2017-12-31 | NT$5.19 Billion ≈ $163.51 Million |
-17.98% |
| 2016-12-31 | NT$6.33 Billion ≈ $199.37 Million |
-13.44% |
| 2015-12-31 | NT$7.31 Billion ≈ $230.34 Million |
+391.30% |
| 2014-12-31 | NT$1.49 Billion ≈ $46.88 Million |
-24.49% |
| 2013-12-31 | NT$1.97 Billion ≈ $62.09 Million |
+125.43% |
| 2012-12-31 | NT$874.17 Million ≈ $27.54 Million |
+67.24% |
| 2011-12-31 | NT$522.72 Million ≈ $16.47 Million |
-- |
About OBI Pharma
OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company's pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has co… Read more